Evidence map›Paper›PMID 19915794›Full record

ArticleClinical and experimental nephrology2010

Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.

Kanyu Miyamoto, Hirohisa Kawai, Ryuhei Aoyama, Hitoshi Watanabe, Keisuke Suzuki, Norihiro Suga, Wataru Kitagawa, Naoto Miura, Kazuhiro Nishikawa, Hirokazu Imai

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Plants (Basel, Switzerland) · 2021
    Review
  3. Article
  4. Licorice abuse: time to send a warning message.Therapeutic advances in endocrinology and metabolism · 2012
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kanyu MiyamotoDivision of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute-cyo, Aichi 480-1195, Japan.
Hirohisa Kawai
Ryuhei Aoyama
Hitoshi Watanabe
Keisuke Suzuki
Norihiro Suga
Wataru Kitagawa
Naoto Miura
Kazuhiro Nishikawa
Hirokazu Imai
Aichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia. He had hypokalemia (K 2.3 mmol/L) induced by licorice and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy. After taking him off all drugs and administering spironolactone supplemented with potassium, his low serum potassium level was ameliorated. Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.

Indexed as

Aged, 80 and overAnti-Arrhythmia AgentsAnti-Bacterial AgentsCytochrome P-450 CYP3ADisopyramideFluoroquinolonesGlycyrrhizaHumansHypokalemiaMaleTorsades de PointesAnti-Arrhythmia AgentsAnti-Bacterial AgentsCYP3A4 protein, humanCytochrome P-450 CYP3ADisopyramideFluoroquinolonesgarenoxacin

Identifiers

PMID19915794
OpenAlexW2021688332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.